Abacus FCF Advisors LLC Acquires New Holdings in Chemed Corporation $CHE

Key Points

• Abacus FCF Advisors LLC established a new position of 13,871 Chemed shares (about $5.94M), and institutional investors now own roughly 95.85% of the company, including a large stake increase by M&T Bank to ~85,934 shares (~$36.8M).
• Chemed beat Q1 adjusted EPS ($5.65 vs. ~ $5.30) and raised FY2026 guidance to $24.00–$24.75, improving the company's near‑term earnings outlook.
• Operational results were mixed—VITAS hospice showed revenue and operating improvements while Roto‑Rooter reported revenue and EBITDA declines—and the company repurchased 500,000 shares and closed two franchise purchases (~$20.6M) as part of capital allocation activity.

Abacus FCF Advisors LLC bought a new position in shares of Chemed Corporation (NYSE:CHE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,871 shares of the company's stock, valued at approximately $5,935,000. Abacus FCF Advisors LLC owned 0.10% of Chemed at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC bought a new position in Chemed during the 4th quarter worth $274,000. Mendel Money Management raised its holdings in Chemed by 85.6% during the 4th quarter. Mendel Money Management now owns 2,890 shares of the company's stock worth $1,237,000 after purchasing an additional 1,333 shares during the last quarter. Diversified Enterprises LLC raised its holdings in Chemed by 19.8% during the 4th quarter. Diversified Enterprises LLC now owns 709 shares of the company's stock worth $303,000 after purchasing an additional 117 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of Chemed by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 15,534 shares of the company's stock worth $6,646,000 after purchasing an additional 1,900 shares during the period. Finally, M&T Bank Corp lifted its position in shares of Chemed by 10,291.1% in the 4th quarter. M&T Bank Corp now owns 85,934 shares of the company's stock worth $36,768,000 after purchasing an additional 85,107 shares during the period. 95.85% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $403.18, for a total transaction of $806,360.00. Following the transaction, the chief executive officer directly owned 93,719 shares in the company, valued at approximately $37,785,626.42. This trade represents a 2.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.29% of the company's stock.

Key Stories Impacting Chemed

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Company raised FY2026 EPS guidance to $24.00–$24.75, above prior consensus, giving investors a better earnings outlook for the year. Chemed Reports First-Quarter 2026 Results
• Positive Sentiment: Adjusted Q1 EPS of $5.65 beat Street estimates (around $5.30), signaling core profitability resilience and helping lift sentiment. Chemed (CHE) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: VITAS (hospice) showed revenue and operating improvements (net patient revenue +3.1%, higher average daily census and admissions), which management cited when raising guidance. Chemed Reports First-Quarter 2026 Results
• Neutral Sentiment: Revenue was roughly flat/only modestly up (+1.6% to $657.5M), essentially in line with expectations — not a growth surprise but not a miss either. Press Release / Slide Deck
• Neutral Sentiment: Cash from operations improved meaningfully and the company repurchased 500,000 shares and closed two Roto‑Rooter franchise purchases (~$20.6M) — capital allocation activity that investors may view positively over time. Chemed Reports First-Quarter 2026 Results
• Negative Sentiment: Roto‑Rooter showed revenue and EBITDA declines and margin compression (notable drop in segment EBITDA and margins), a near‑term drag on consolidated profitability. Chemed earnings on deck as hospice, plumbing units face tests
• Negative Sentiment: GAAP diluted EPS and net income were slightly down year‑over‑year, and balance‑sheet notes (lower cash, higher liabilities) plus recent insider sales may concern some investors focused on capital structure. Chemed Corp (CHE) Stock Rises on Q1 2026 Earnings

Chemed Price Performance

Shares of NYSE CHE opened at $420.67 on Friday. The company has a 50-day moving average price of $403.17 and a 200-day moving average price of $426.24. The stock has a market capitalization of $6.15 billion, a P/E ratio of 22.92, a P/E/G ratio of 1.52 and a beta of 0.49. Chemed Corporation has a 1 year low of $365.20 and a 1 year high of $583.96.

Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping analysts' consensus estimates of $5.30 by $0.35. The company had revenue of $657.51 million for the quarter, compared to analyst estimates of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 25.70%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.63 EPS. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities research analysts anticipate that Chemed Corporation will post 21.92 earnings per share for the current fiscal year.

Chemed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 13th. Investors of record on Monday, February 23rd were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, February 23rd. Chemed's dividend payout ratio is presently 13.08%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CHE shares. Jefferies Financial Group cut shares of Chemed from a "buy" rating to a "hold" rating in a research report on Thursday, January 22nd. Oppenheimer dropped their price objective on Chemed from $580.00 to $500.00 and set an "outperform" rating on the stock in a research note on Friday, February 27th. Royal Bank Of Canada restated a "sector perform" rating and set a $422.00 target price (down from $572.00) on shares of Chemed in a research report on Friday, February 27th. Zacks Research lowered Chemed from a "hold" rating to a "strong sell" rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings cut Chemed from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, April 13th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $498.00.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.